ASP Isotopes Inc. saw a significant price increase of 24.69%, as the stock crossed above its 5-day SMA, reflecting a strong upward movement in the market.
This surge comes amid an ongoing investigation into the company by Kahn Swick & Foti, focusing on potential breaches of fiduciary duties by its executives. The court's decision to allow a securities class action lawsuit to proceed could expose ASP to substantial financial liabilities and reputational damage. Additionally, allegations from Fuzzy Panda Research regarding misleading information about the company's nuclear fuel technologies may undermine investor confidence, suggesting a potential sector rotation as investors reassess their positions.
The implications of these legal challenges could be significant for ASP Isotopes Inc., as they may affect corporate governance and shareholder trust. Investors will be closely monitoring the developments of the lawsuit and the company's response to the allegations.
Wall Street analysts forecast ASPI stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ASPI is 13.00 USD with a low forecast of 11.00 USD and a high forecast of 15.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Analyst Rating
Wall Street analysts forecast ASPI stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ASPI is 13.00 USD with a low forecast of 11.00 USD and a high forecast of 15.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 7.240
Low
11.00
Averages
13.00
High
15.00
Current: 7.240
Low
11.00
Averages
13.00
High
15.00
Cantor Fitzgerald
Derek Soderberg
Overweight
initiated
$13
2025-12-04
Reason
Cantor Fitzgerald
Derek Soderberg
Price Target
$13
AI Analysis
2025-12-04
initiated
Overweight
Reason
Cantor Fitzgerald analyst Derek Soderberg initiated coverage of ASP Isotopes (ASPI) with an Overweight rating and $13 price target. ASP Isotopes has developed advanced isotope-enrichment technology that produces high-value nuclear fuel, medical isotopes, and silicon-28, and currently stands as the sole commercial-scale provider of certain isotopes, the analyst tells investors in a research note. The pending acquisition of Renergen (RGNNF) could give ASPI control of the world's largest high-concentration helium deposit, while the planned spinout of its quantum laser enrichment technology represents a near-term value-creation opportunity, Cantor says.
Cantor Fitzgerald
Derek Soderberg
initiated
$13
2025-12-04
Reason
Cantor Fitzgerald
Derek Soderberg
Price Target
$13
2025-12-04
initiated
Reason
Cantor Fitzgerald analyst Derek Soderberg initiated coverage of ASP Isotopes with an Overweight rating and $13 price target.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for ASPI
Unlock Now
Lucid Capital
Alex Fuhrman
Buy
initiated
$15
2025-10-27
Reason
Lucid Capital
Alex Fuhrman
Price Target
$15
2025-10-27
initiated
Buy
Reason
Lucid Capital analyst Alex Fuhrman initiated coverage of ASP Isotopes with a Buy rating and $15 price target. The company is "entering a phase of rapid growth" as it transitions to commercial production of isotopes with the potential to transform a wide range of high-tech industries, the analyst tells investors in a research note. The firm sees ASP as well positioned to help reduce the West's dependence on Russian isotope supplies critical to medicine and nuclear power.
Canaccord
Buy
upgrade
$11
2025-05-21
Reason
Canaccord
Price Target
$11
2025-05-21
upgrade
Buy
Reason
Canaccord raised the firm's price target on ASP Isotopes to $11 from $8.50 and keeps a Buy rating on the shares. The firm said they are positive on the multiple definitive agreements with TerraPower, "related to financing support for the construction of a new uranium enrichment facility capable of producing High Assay Low-Enriched Uranium (HALEU), and the future supply of HALEU to TerraPower, as a customer." Canaccord raised its estimates and they see room for further upside with the announced transaction and management's ability to execute.
About ASPI
ASP Isotopes Inc. is a development stage advanced materials company. The Company is engaged in the development of technology and processes to produce isotopes for use in multiple industries. The Company employs proprietary technology, the Aerodynamic Separation Process (ASP technology). Its initial focus is on producing and commercializing highly enriched isotopes for the healthcare and technology industries. Its Nuclear Fuels segment is focused on research and development of technologies and methods used to produce high-assay low-enriched uranium (HALEU) and Lithium-6 for the advanced nuclear fuels target end market. Its Specialist Isotopes and Related Services segment is focused on research and development of technologies and methods used to separate high-value, low-volume isotopes (such as C-14, Mo-100, and Si-28) for highly specialized target end markets other than advanced nuclear fuels, including pharmaceuticals and agrochemicals, nuclear medical imaging, and others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
